相关实验视频

Updated: Jul 20, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

探索ERBB2-改变的高级非小细胞肺癌的第一线治疗:一个多中心的回顾性研究

Jiayan Chen¹, Chunwei Xu², Qian Wang³

¹Department of Respiratory Medicine, Affiliated Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu 210002, China.

Lung cancer (Amsterdam, Netherlands)

|July 30, 2023

概括

评估了ERBB2改变的非小细胞肺癌 (NSCLC) 的一线治疗方法. 包括免疫疗法或抗血管生成在内的组合疗法比单独的向治疗改善了生存效益.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

具有ERBB2变化的非小细胞肺癌 (NSCLC) 存在独特的治疗挑战.
现有的研究缺乏对ERBB2变异NSCLC的第一线治疗方法的全面评估.
免疫治疗的进步需要重新评估治疗策略.

研究的目的:

评估ERBB2-改变NSCLC的各种一线治疗方案的疗效.
为了比较单独的化疗,抗ERBB2氨酸激酶抑制剂 (TKI) 和组合疗法之间的结果.
评估免疫疗法和抗血管生成药对患者存活率的影响.

主要方法:

一项多中心回顾性研究招募了ERBB2改变NSCLC的患者.
治疗组包括化疗 (化疗),抗ERBB2TKI,化疗+免疫治疗 (免疫),化疗+抗血管生成 (抗血管),以及化疗+免疫+抗血管.
评估的临床结果是客观应答率 (ORR),疾病控制率 (DCR) 和无进展生存时间 (mPFS) 中位数.

主要成果:

总体客观应答率 (ORR) 为30.8%,中位数无进展生存期 (mPFS) 为5.7个月.
与免疫疗法 (化疗 + 免疫) 和抗血管生成 (化疗 + 抗血管) 结合的化疗与TKIs相比,证明了较长的mPFS.
在组合疗法和单独化疗之间没有观察到mPFS的显著差异,尽管组合疗法显示出更长的mPFS.

结论:

结合免疫疗法或抗血管生成的第一线化疗可能与单独针对ERBB2-改变的NSCLC的ERBB2-向治疗相比,提供更好的生存益处.
这些组合疗法的疗效可能不会超过单独的化疗.
需要进一步的研究来优化这种患者群体的第一线治疗策略.

关键词:

这是ERBB2的变化.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.现实世界的研究研究.治疗方法治疗方法

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...